Inthelia Therapeutics aims to develop a novel, non-antibiotic approach to treat and prevent severe bloodstream infections. We are a clinical-stage biotechnology research company that target early to intermediate stages of sepsis occurring from bacterial, viral, and fungal infections. Built on unparalleled and leading-edge experimental approaches across the fields of computational, structural, and functional biology, we identify critical pathways used by major human pathogens. We believe we have a unique approach to sepsis therapy by introducing unprecedented host-directed therapeutics to block sepsis in early phases, which circumvents the issue surrounding antimicrobial resistance.
Company Details
- Employees
- 3
- Founded
- -
- Address
- Rcsi University Of Medicine And Health Sciences, Dublin,ireland
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.inthelia.com
- HQ
- Dublin
Inthelia Therapeutics Questions
Inthelia Therapeutics's website is http://www.inthelia.com
Inthelia Therapeutics's LinkedIn profile is https://ie.linkedin.com/company/inthelia-therapeutics
Inthelia Therapeutics has
3 employees.
View email and phone details for 3
employees at Inthelia Therapeutics.
Inthelia Therapeutics's industry is
Biotechnology Research
Inthelia Therapeutics's top competitors are
Pumpinheart,
Oncolize,
Probmet Therapeutics,
Cellgebra,
Plio Surgical,
Tympulse Medical,
Atxa Therapeutics,
Phyxiom,
Sublimity Therapeutics,
Lep Biomedical.
Inthelia Therapeutics's categories are Biotechnology Research
Inthelia Therapeutics's founding year is 2021
